Protocol Ledger

NCT04930042 · Phase III · COMPLETED

Efficacy, Safety, and Immunogenicity of AVT04 With Moderate-to-Severe Chronic Plaque Psoriasis

Interventional Phase III clinical trial protocol NCT04930042 sponsored by Alvotech Swiss AG in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-06-03 Enrollment: 581 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04930042
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)581 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04930042
Protocol FieldVerified Registry Value
NCT IdentifierNCT04930042
Consolidated Lead SponsorAlvotech Swiss AG
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment581 participants (ACTUAL)
Registered Start Date2021-06-03
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04930042
Hospital Research SiteLocationSite Profile
Centrum Badan Klinicznych PI-House sp. z o.o.Gdansk, PolandOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI